July 28, 2014 7:09 PM ET

Capital Markets

Company Overview of The Biotech Growth Trust PLC

Company Overview

The Biotech Growth Trust PLC is a closed ended equity mutual fund launched and managed by Frostrow Capital LLP. It is co-managed by OrbiMed Capital LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the biotechnology sector. The fund invests in stocks of companies across all market capitalizations. It employs fundamental analysis to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotechnology Index. It was previously known as Finsbury Emerging Biotechnology Trust PLC. The Biotech Growth Trust PLC was formed on May 20, 1997 and is domiciled in the United Kingdom.

601 Lexington Avenue

54th Floor

New York, NY 10022

United States

Founded in 1997

Phone:

212-739-6400

Fax:

212-739-6444

Key Executives for The Biotech Growth Trust PLC

Portfolio Manager
Age: 46
Portfolio Manager
Partner and Co-Portfolio Manager
Portfolio Manager
Age: 69
Portfolio Manager
Compensation as of Fiscal Year 2014.

The Biotech Growth Trust PLC Key Developments

The Biotech Growth Trust PLC Reports Audited Earnings Results for the Year Ended March 31, 2014

The Biotech Growth Trust PLC reported audited earnings results for the year ended March 31, 2014. For the year, the company reported total income of GBP 873,000 against GBP 570,000 for the same period in the last year. Profit before finance costs and taxation was GBP 86,525,000 against GBP 76,224,000 for the same period in the last year. Profit before taxation was GBP 86,431,000 against GBP 76,206,000 for the same period in the last year. Profit was GBP 86,337,000 or 126.8 pence per basic and diluted share against GBP 76,148,000 or 121.1 pence per basic and diluted share for the same period in the last year. Net asset value per share was 498.7 pence as at March 31, 2014 against 371.7 pence as at March 31, 2013. Net cash outflow from operating activities was GBP 52,246,000 against net cash inflow from operating activities of GBP 1,154,000 for the same period in the last year.

The Biotech Growth Trust PLC, Annual General Meeting, Jul 10, 2014

The Biotech Growth Trust PLC, Annual General Meeting, Jul 10, 2014., at 12:30 GMT Standard Time. Location: Barber-Surgeons' Hall, Monkwell Square. Agenda: To receive and, if thought fit, to accept the audited financial statements and the report of the directors for the year ended March 31, 2014; to approve the directors' remuneration report for the year ended March 31, 2014; to receive and approve the remuneration policy; to re-elect The Rt Hon Lord Waldegrave of North Hill as a director of the company; to re-elect Professor Dame Kay Davies, DBE as a director of the company; to re-elect Andrew Joy as a director of the company; to re-elect Sven Borho as a director of the company; to re-elect Paul Gaunt as a director of the company; to re-elect Peter Keen as a director of the company; to appoint Ernst & Young LLP as auditors to the company and to authorize the directors to determine their remuneration; to grant authority to allot shares; to consider disapplication of pre-emption rights; to consider authority to repurchase ordinary shares; to adopt new articles of association; and to consider other matters.

The Biotech Growth Trust PLC Reports Unaudited Earnings Results for the Half Year Ended September 30, 2013

The Biotech Growth Trust PLC reported unaudited earnings results for the half year ended September 30, 2013. For the period, the company reported total income of £477,000 against £328,000 a year ago. Profit before taxation was £45,562,000 against £28,901,000 a year ago. Profit was £45,518,000 or 67.3 pence basic and diluted per share against £28,877,000 or 46.1 pence basic and diluted per share a year ago. Net cash outflow from operating activities was £34,540,000 against net cash inflow from operating activities of £10,020,000 a year ago. The revenue loss for the period was £36,000.

Similar Private Companies By Industry

Company Name Region
Chessiecap Securities, Inc. United States
Auramet Trading, LLC United States
Ewing Bemiss & Co. United States
Hewitt EnnisKnupp United States
Doctors Link Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
July 30, 2013
Trius Therapeutics, Inc.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The Biotech Growth Trust PLC, please visit www.frostrow.com/clients/biotech. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.